2012肝癌臨床實(shí)踐指南
《2012肝癌臨床實(shí)踐指南》內(nèi)容簡介：
Hepatobiliary cancers are highly lethal cancers including a spectrum ofinvasive carcinomas arising in the liver （hepatocellular carcinoma;HCC）， bile ducts （intrahepatic and extrahepatic cholangiocarcinoma）and gall bladder. Cholangiocarcinomas and gallbladder cancer arecollectively known as biliary tract cancers. In the United States, anestimated 26,190 and 9,250 cases will be diagnosed with liver orintrahepatic bile duct cancer and gallbladder cancer or other biliary tractcancer, respectively in 2011 with approximately 19,590 deaths fromliver or intrahepatic bile duct cancer, and 3,300 deaths due togallbladder cancer or other biliary tract cancer occurring during thatyear.
《2012肝癌臨床實(shí)踐指南》內(nèi)容預(yù)覽：
For patients with an incidental liver mass or nodule found onultrasound, the guidelines recommend evaluation using one or more ofthe imaging modalities （at least a 3-phase contrast-enhanced CT orMRI including the arterial and portal venous phase） to determine theperfusion characteristics, extent and the number of lesions, vascularanatomy and extrahepatic disease. The number and type of imaging isdependent on the size of the liver mass or nodule.
Liver lesions less than 1 cm should be evaluated by at least a 3-phasecontrast-enhanced CT or MRI or CEUS every 3-6 months, withenlarging lesions evaluated according to size. Patients with lesionsstable in size should be followed with imaging every 3-6 months usingthe same imaging modality that was first used to identify the nodules.
點(diǎn)擊下載***：《2012肝癌臨床實(shí)踐指南》
本站所注明來源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們
聯(lián)系z(mì)lzs@120.net，我們將立即進(jìn)行刪除處理
熱點(diǎn)圖文
-
參與應(yīng)激后高代謝反應(yīng)的主要因素是什么?
研究表明,機(jī)體在創(chuàng)傷、感染等應(yīng)激后出現(xiàn)的以分解代謝占優(yōu)勢(shì)的高代謝狀態(tài)的主要...[詳細(xì)]
-
創(chuàng)傷、感染后的生理與代謝改變主要有哪些?
機(jī)體在遭受感染、創(chuàng)傷、大出血、大手術(shù)等打擊后將發(fā)生以高代謝狀態(tài)為特征的應(yīng)激...[詳細(xì)]
